AMPE — Ampio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Ampio Pharmaceuticals Says Michael Martino To Become Interim Chairman And CEO
Brief: Ampio Pharmaceuticals Posts Quarterly Loss Per Share Of $0.02
Brief: Ampio Pharmaceuticals Inc Strengthens Management Team And Board Of Directors
Brief: Ampio Pharmaceuticals Inc Receives Approval From The Drugs Controller General Of India (DCGI) To Commence AP-019 Phase II Study In India
Ampio Pharma rises on positive data from joint disease study
Brief: Ampio Reports Top-line Results from Study of Ampion in Adult Patients With Severe Osteoarthritis of Knee
Brief: Ampio Pharmaceuticals Reports Q2 2021 Financial Results
Brief: Ampio Pharmaceuticals Announces Patient Randomization And Dosing In AP-019 Phase Ii Study Of Inhaled Ampion In Covid-19 Respiratory Distress
Ampio Pharma rises after dosing begins in COVID-19 drug study
Brief: Ampio Pharmaceuticals, Inc. To Join The Russell 2000® Index And Russell 3000® Index
Brief: Ampio Provides Update On Osteoarthritis Of The Knee (Oak) Program, Reiterates Compelling Data In Earlier Phase Iii Trials Of Ampion In Severe Oak
Brief: Ampio Pharmaceuticals Receives Approval To Expand Enrollment Of Its AP-019 Phase Ii Study To India
Ampio Pharma: Rises on expansion of COVID-19 drug study to India
Advisory: Multiple dated alerts withdrawn
Brief: Ampio Pharmaceuticals Reports Q1 Loss Per Share Of $0.02
Brief: Ampion Reduces All-Cause Mortality In Covid-19 Respiratory Distress By Nearly 80%
Brief: Ampio Pharmaceuticals' Study Shows Ampion Inhibits Key Inflammatory Pathway In COVID-19 And Lupus Nephritis
Brief: Ampio Pharmaceuticals Details Early Positive Results For Inhaled Ampion In Covid-19 Respiratory Distress
Brief: Ampio Pharmaceuticals Reports Q4 2020 Financial Results